The Fund aims to achieve an income return, together with long-term capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 7.3% |
BP | 5.1% |
BABCOCK INTERNATIONAL GROUP | 4.8% |
MELROSE | 4.2% |
RSA INSURANCE GROUP PLC | 3.8% |
REED ELSEVIER | 3.6% |
HOWDEN JOINERY GROUP PLC | 3.5% |
GKN | 3.3% |
BG GROUP | 3.1% |
COMPASS GROUP | 3.0% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 7.3% |
BP | 5.1% |
BABCOCK INTERNATIONAL GROUP | 4.8% |
MELROSE | 4.2% |
Other | 78.6% |
Date | 02-Mar-2022 |
---|---|
NAV | 379.30p |
Currency | GBP |
Change | -7.10p |
% | -1.84% |
YTD change | 379.30p |
YTD % | n/a |
Fund Inception | 03/11/1989 |
---|---|
Fund Manager | Julie Dean |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | n/a |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.11 |
You are here: research